The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
Outer Bio
A discovery platform combining long-lived ex vivo human skin models with machine learning.
What they do
Outer Bio uses its Yuna human-skin platform, automated screening and machine learning to discover skin mechanisms and bioactive compounds.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Human skin models and AI discovery
- Product type
- Platform software
- Stage
- Seed
- Headquarters
- Not disclosed
- Region
- North America
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
DDDr. Dereck Mush, MD, MBA
Jun 5
AI is moving upstream, from molecule design into disease target identification itself
DDDr. Dereck Mush, MD, MBA
Mar 18The HealthTech Signal
The Lawsuit Alleging an Algorithm, Not a Doctor, Decided When Grandma's Care Ended
The Lawsuit Alleging an Algorithm, Not a Doctor, Decided When Grandma's Care Ended
DDDr. Dereck Mush, MD, MBA
Jun 3